In the Journals

UC patients treated with Entyvio as first biologic therapy could see better outcomes

Patients with moderate-to-severe ulcerative colitis treated with Entyvio as first-line biologic therapy could experience better outcomes, according to research published in Inflammatory Bowel diseases.

Frank I. Scott, MD, MSCE, assistant professor of medicine at the University of Colorado School of Medicine, and colleagues wrote that with recent advances in available therapies for the treatment of ulcerative colitis (UC), developing the right treatment program has become much more complex.

The investigators simulated 100 trials of 100,000 patients with outcomes assessed regarding quality adjusted life years to determine the best position of Entyvio (vedolizumab, Takeda) in the UC treatment paradigm.

“In the absence of clinical trials comparing treatment algorithms for ulcerative colitis, analyses like this simulation provide tools for helping the clinical community determine the best ways to incorporate specific therapies into practice,” Scott said in a press release.

For the simulation, Scott and colleagues used a Markov model designed to replicate real-world situations using previous clinical data. They tested different positioning for vedolizumab therapy based on the case of a 35-year-old man with moderate-to-severe UC and a steroid dependency.

They found that the patients in the simulation who used vedolizumab prior to all other therapies had 8,981 more remissions, 18 fewer cases of lymphoma and 1,087 fewer serious infections per 100,000 patients compared with the simulation that used vedolizumab as the final therapy.

Scott and colleagues wrote that further research is needed to confirm the simulated results.

“The resulting data help provide valuable insights for health care providers evaluating the sequence of therapies for certain patients with ulcerative colitis early in the treatment algorithm,” Scott said in the press release. by Alex Young

Disclosures: Scott reports he received support via a research grant provided by Takeda Pharmaceuticals. Please see full study for the other authors’ relevant financial disclosures.

Patients with moderate-to-severe ulcerative colitis treated with Entyvio as first-line biologic therapy could experience better outcomes, according to research published in Inflammatory Bowel diseases.

Frank I. Scott, MD, MSCE, assistant professor of medicine at the University of Colorado School of Medicine, and colleagues wrote that with recent advances in available therapies for the treatment of ulcerative colitis (UC), developing the right treatment program has become much more complex.

The investigators simulated 100 trials of 100,000 patients with outcomes assessed regarding quality adjusted life years to determine the best position of Entyvio (vedolizumab, Takeda) in the UC treatment paradigm.

“In the absence of clinical trials comparing treatment algorithms for ulcerative colitis, analyses like this simulation provide tools for helping the clinical community determine the best ways to incorporate specific therapies into practice,” Scott said in a press release.

For the simulation, Scott and colleagues used a Markov model designed to replicate real-world situations using previous clinical data. They tested different positioning for vedolizumab therapy based on the case of a 35-year-old man with moderate-to-severe UC and a steroid dependency.

They found that the patients in the simulation who used vedolizumab prior to all other therapies had 8,981 more remissions, 18 fewer cases of lymphoma and 1,087 fewer serious infections per 100,000 patients compared with the simulation that used vedolizumab as the final therapy.

Scott and colleagues wrote that further research is needed to confirm the simulated results.

“The resulting data help provide valuable insights for health care providers evaluating the sequence of therapies for certain patients with ulcerative colitis early in the treatment algorithm,” Scott said in the press release. by Alex Young

Disclosures: Scott reports he received support via a research grant provided by Takeda Pharmaceuticals. Please see full study for the other authors’ relevant financial disclosures.

    See more from Ulcerative Colitis Resource Center